Trials / Unknown
UnknownNCT06078982
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Efficacy and Safety of Disitamab Vedotin Combined With PD-1 in Posterior Line Therapy of Advanced HER2-low Expressing Gastric Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Shanghai East Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, prospective, non-randomized, multi-center/single-center, open-label, phase I clinical study aimed at evaluating the efficacy and safety of Disitamab Vedotin in combination with PD-1 as posterior line treatment for patients with advanced HER2-low expressing gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Disitamab Vedotin | 2.0mg/kg, intravenously D1, once every 14 days (Q2W) |
| DRUG | Toripalimab | 3.0 mg/kg, once every 14 days (Q2W) |
Timeline
- Start date
- 2023-06-06
- Primary completion
- 2025-08-01
- Completion
- 2025-08-01
- First posted
- 2023-10-12
- Last updated
- 2023-10-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06078982. Inclusion in this directory is not an endorsement.